Correlation between Serum miR-34a Level and Thrombocytopenia after Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2022.03.020
- Author:
Hong-Li ZHANG
1
;
Adina UTICUL
1
;
Xiao-Wei XU
1
;
Yu-Wei SHI
2
Author Information
1. Department of Hematology, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830063, China.
2. Department of Hematology, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830063, China,E-mail: 443846579@qq.com.
- Publication Type:Journal Article
- Keywords:
chemotherapy;
correlation;
diffuse large B-cell lymphoma;
miR-34a;
thrombocytopenia
- MeSH:
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Cyclophosphamide;
Doxorubicin;
Humans;
Interleukin-11/therapeutic use*;
Lymphoma, Large B-Cell, Diffuse/genetics*;
MicroRNAs/genetics*;
Prednisone/therapeutic use*;
Prognosis;
RNA, Messenger;
Rituximab/therapeutic use*;
Thrombocytopenia;
Vincristine
- From:
Journal of Experimental Hematology
2022;30(3):784-789
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the relationship between serum miR-34a level and thrombocytopenia after chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL).
METHODS:A total of 69 eligible DLBCL patients who received chemotherapy in our hospital from January 2018 to January 2020 were prospectively included as the research subjects, all patients received R-CHOP 21 regimen (rituximab + cyclophosphamide + adriamycin + vincristine + prednisone) for chemotherapy, 3 weeks was 1 cycle, and 2 cycles of chemotherapy were used. The patients were divided into a reduction group and a non reduction group according to whether there was thrombocytopenia after chemotherapy, the general data and laboratory indexes of the two groups were investigated and compared, the relationship between serum miR-34a before chemotherapy and thrombocytopenia after chemotherapy in patients was analyzed.
RESULTS:Among the 69 DLBCL patients, 36 patients developed thrombocytopenia after 2 cycles of R-CHOP 21 regimen for chemotherapy, the incidence was 52.17%; the level of serum IL-11 and the relative expression of miR-34a mRNA in the reduction group were significantly lower than the non reduction group (P<0.05), compared other data between groups, there was no statistical significant difference (P>0.05); after Logistic regression analysis, the results showed that the level of serum IL-11 and the relative expression of miR-34a mRNA were related to thrombocytopenia after chemotherapy in DLBCL patients, low expression of each index may be a risk factor of thrombocytopenia after chemotherapy in DLBCL patients (OR>1, P<0.05); ROC curve was drawn, and the results showed that the AUC of serum IL-11 level and miR-34a mRNA relative expression before chemotherapy alone and in combination predicted the risk of thrombocytopenia after chemotherapy in DLBCL patients were all >0.80, and the predictive value was ideal, when the cut-off value of serum IL-11 level before chemotherapy was 42.094 pg/ml, and the cut-off value of miR-34a mRNA relative expression was 3.894, the combined prediction value was the best.
CONCLUSION:The relative expression of miR-34a mRNA is associated with thrombocytopenia after chemotherapy in DLBCL patients, which may be a risk factor for thrombocytopenia in patients after chemotherapy, has certain value in predicting the risk of thrombocytopenia of patients after chemotherapy.
